Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (KTTA)
CUSIP: 70261F202
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.0001
- Shares outstanding
- 24,858,270
- Total 13F shares
- 12,892,082
- Share change
- +10,180,078
- Total reported value
- $16,641,289
- Price per share
- $1.29
- Number of holders
- 24
- Value change
- +$13,193,231
- Number of buys
- 17
- Number of sells
- 8
Quarterly Holders Quick Answers
What is CUSIP 70261F202?
CUSIP 70261F202 identifies KTTA - Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q3 2025
Recent filing periods for CUSIP 70261F202:
Top shareholders of KTTA - Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
— |
10%
|
17,560,467
|
$12,292,327 | $0 | 01 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13D/G
|
— |
10%
|
10,229,652
|
$7,160,756 | $0 | 28 Nov 2025 | |
| Adage Capital Management, L.P. |
13D/G
|
— |
10%
|
2,329,749
|
$2,050,179 | $0 | 31 Dec 2025 | |
| Squadron Capital Management LLC |
13D/G
|
Squadron Master Fund LP |
9.9%
|
2,329,749
|
$2,050,179 | +$67,601 | 31 Dec 2025 | |
| AMERIPRISE FINANCIAL INC |
13D/G
|
— |
8.4%
|
1,930,128
|
$1,698,513 | $0 | 31 Dec 2025 | |
| PD Joint Holdings, LLC Series 2016-A |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,608,696
|
$1,124,348 | — | 22 Oct 2022 | |
| CVI Investments, Inc. |
13D/G
|
— |
3.8%
|
899,994
|
$791,995 | +$64,987 | 31 Dec 2025 | |
| Eric Shahinian |
3/4/5
|
Member of 10% owner group |
—
class O/S missing
|
1,788,415
|
$770,807 | — | 28 Sep 2022 | |
| Orca Capital AG |
13D/G
|
— |
4.9%
|
362,857
|
$613,228 | -$14,002 | 07 May 2025 | |
| INTRACOASTAL CAPITAL, LLC |
13D/G
|
Mitchell P. Kopin |
5%
|
317,863
|
$537,188 | $0 | 06 May 2025 | |
| Israel Maxx Abramowitz |
3/4/5
|
Not a 10% owner |
—
class O/S missing
|
1,051,575
|
$453,229 | — | 14 Sep 2021 | |
| Dean Lazer |
3/4/5
|
Not a 10% owner |
—
class O/S missing
|
902,600
|
$389,021 | — | 14 Sep 2021 | |
| Eric Lazer |
3/4/5
|
Not a 10% owner |
—
class O/S missing
|
902,600
|
$389,021 | — | 14 Sep 2021 | |
| ARMISTICE CAPITAL, LLC |
13D/G
13F
|
Company |
5%
|
142,082
|
$240,119 | +$14,019 | 31 Mar 2025 | |
| AdvisorShares Investments LLC |
13F
|
Company |
1%
|
257,696
|
$185,567 | — | 30 Sep 2025 | |
| Lawrence Steinman |
3/4/5
13D/G
|
Director |
3.1%
from 13D/G
|
442,604
mixed-class rows
|
$149,768 | +$100,000 | 28 Nov 2025 | |
| Dr. Yassine Bendiabdallah |
3/4/5
|
Chief Operating Officer, Director |
—
class O/S missing
|
300,000
|
$129,300 | — | 14 Sep 2021 | |
| David Delaney |
3/4/5
|
Member of 10% owner group |
—
class O/S missing
|
227,521
|
$98,062 | — | 17 Oct 2022 | |
| Dr. Tiago Reis Marques |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
566,675
mixed-class rows
|
$55,000 | +$24,208 | 28 Nov 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
—
mixed-class rows
|
82,532
mixed-class rows
|
$48,699 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.22%
|
53,815
|
$38,747 | — | 30 Sep 2025 | |
| Simon Dumesnil |
3/4/5
|
Director |
—
mixed-class rows
|
78,746
mixed-class rows
|
$26,874 | +$25,000 | 28 Nov 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.14%
|
35,760
|
$26,169 | — | 30 Sep 2025 | |
| Dr. Emer Leahy |
3/4/5
|
Director |
—
mixed-class rows
|
76,246
mixed-class rows
|
$24,999 | — | 28 Nov 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.14%
|
34,358
|
$24,741 | — | 30 Sep 2025 | |
| Avi Geller |
3/4/5
|
Member of 10% owner group |
—
class O/S missing
|
54,644
|
$23,552 | — | 19 Aug 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.12%
|
30,700
|
$22,466 | — | 30 Sep 2025 | |
| Daniel H. Schneiderman |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
343,933
mixed-class rows
|
$20,000 | — | 28 Nov 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.1%
|
25,475
|
$18,347 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.1%
|
25,053
|
$18,334 | — | 30 Sep 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.1%
|
25,075
|
$18,000 | — | 30 Sep 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.08%
|
20,846
|
$15,255 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.07%
|
18,381
|
$13,455 | — | 30 Sep 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.04%
|
10,896
|
$7,000 | — | 30 Sep 2025 | |
| Kepos Capital LP |
13F
|
Company |
—
class O/S missing
|
334,600
|
$6,000 | — | 30 Sep 2025 | |
| Hurley Capital, LLC |
13F
|
Company |
0.01%
|
3,689
|
$2,700 | — | 30 Sep 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
1,217
|
$891 | — | 30 Sep 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
1,051
|
$769 | — | 30 Sep 2025 | |
| Marex Group plc |
13F
|
Company |
—
class O/S missing
|
25,000
|
$423 | — | 30 Sep 2025 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
443
|
$319 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
—
class O/S missing
|
14,586
|
$247 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
150
|
$108 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
58
|
$43 | — | 30 Sep 2025 | |
| Alfred J. Novak |
3/4/5
|
Director |
—
class O/S missing
|
42,913
|
— | — | 24 Oct 2025 | |
| Graeme Martin Currie |
3/4/5
|
Chief Development Officer |
—
class O/S missing
|
5,938
|
— | — | 01 Mar 2024 |
Institutional Holders of Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (KTTA) as of Q4 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.